Clinical and Medical Affairs
Signal Detection.
Identify safety signals in clinical data early on—and take the right action. We implement structured detection processes in accordance with GVP Module IX to ensure proactive drug safety rather than reactive crisis management.
Why is signal detection critical for pharmaceutical companies?
GVP Module IX requires European marketing authorization holders to conduct systematic signal detection. Non-compliance in this area has serious consequences:
- Failure to detect safety signals can lead directly to government intervention, costly recalls, and, in the worst case, the revocation of a product’s approval.
- Purely reactive, ad hoc signal assessments without a clearly documented process constitute a formal GCP non-compliance.
- In-house signal data (from ICSR and studies) must be integrated with Eudravigilance and literature data in a thorough and methodologically sound manner.
- Delays in signal evaluation inevitably trigger formal inquiries from the authorities.
Do you already have a fully documented, verifiable, and regularly performed signal detection process in place?
Our signal detection services.
We help you transform signal detection from a mere compliance process into an active, protective safety management system.
Signal Detection System Setup
Professional design of a comprehensive signal detection process in strict accordance with GVP Module IX. We define data sources, detection methodologies, strict evaluation criteria, documentation standards, and reporting procedures to ensure seamless integration into your PV system.
Quantitative and Qualitative Signal Analysis
Application of established statistical methods (disproportionality analysis, ROR, PRR) to large Eudravigilance datasets. Supplemented by an in-depth qualitative assessment of clinical case reports, literature sources, and registry data.
Signal Management & Risk Assessment
A structured approach to signal triage and evaluation: Is a signal validated, potentially relevant, or negligible? For validated signals, we develop targeted risk minimization measures (RMMs) for your risk management.
GVP Module IX: Audit & Gap Analysis
An independent, critical assessment of your existing signal detection system against the stringent requirements of GVP Module IX. We identify process gaps and methodological weaknesses and provide an actionable CAPA plan.
Frequently Asked Questions About Signal Detection.
What exactly is a safety signal in pharmacovigilance?
A signal is specific information that indicates a possible new causal relationship between a drug and an adverse event—or suggests that a previously known relationship has changed in clinical significance. Such signals typically arise from ICSR data, medical literature, patient registries, or clinical trials.
What is the Disproportionality Analysis (DPA)?
Disproportionality analysis (DPA) is an established statistical method for quantitative signal detection in large pharmacovigilance databases. It uses mathematical calculations to determine whether a specific drug-event combination is reported significantly more frequently than would be expected based on statistical probability alone. Common statistical measures for this are the Reporting Odds Ratio (ROR) and the Proportional Reporting Ratio (PRR).
How often must signal detection be performed by law?
Although GVP Module IX does not prescribe a rigid, fixed frequency, it does require a risk-based approach. Typically, it is conducted monthly for newly approved products and quarterly for well-established products. Both the frequency and the methodology must be clearly documented in the Pharmacovigilance System Master File (PSMF).
Do identified safety signals have to be reported to the EMA immediately?
In the case of so-called validated signals concerning products authorized in the EU, the EMA or the competent national authority must generally be notified. The exact timeframe depends on the priority of the signal: for critical signals, notification must occur almost immediately; for signals of lower priority, notification may take place within the next regular PSUR reporting period.
Additional expertise in pharmacovigilance.
Submit a project inquiry.
Please briefly describe your current challenge. An expert from our team will contact you shortly.